c-Met/HGFR

Related Products

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

c-Met/HGFR Related Products (160)
Recombinant Proteins (15)
Antibodies (5)

By Effects:	Inhibitors (153) Agonist (1) Degrader (1) Activators (2) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-10991

MGCD-265 analog	Inhibitor	98.47%
MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2/KDR/Flk-1 tyrosine kinases, with IC₅₀s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.

HY-13299

MK-8033	Inhibitor	98.34%
MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs).

HY-100946

CEP-40783	Inhibitor	99.12%
CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.

HY-15240

c-Kit-IN-1	Inhibitor	98.83%
c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC₅₀s of <200 nM.

HY-100509

NPS-1034	Inhibitor	≥98.0%
NPS-1034 is a dual inhibitor of AXL and MET with IC₅₀s of 10.3 and 48 nM, respectively.

HY-147040

ABN401	Inhibitor	99.19%
ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC₅₀ value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer.

HY-132814

Fosgonimeton	Agonist	99.61%
Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor agonist (WO2017210489).

HY-13299A

MK-8033 hydrochloride	Inhibitor	99.86%
MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs).

HY-14723

AMG-458	Inhibitor	98.18%
AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with K_i values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively.

HY-114357A

DS-1205b free base	Inhibitor	99.92%
DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC₅₀ of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC₅₀s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.

HY-12035

AMG-208	Inhibitor	99.86%
AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC₅₀ of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC₅₀ of 32 μM. AMG-208 has anti-cancer activity.

HY-P99217

Rilotumumab	Inhibitor	99.10%
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

HY-12423A

Pamufetinib mesylate	Inhibitor	99.19%
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC₅₀s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

HY-P99196

Ficlatuzumab	Inhibitor	99.21%
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.

HY-18309

MET kinase-IN-4	Inhibitor	99.46%
MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC₅₀ value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer.

HY-50878S

Crizotinib-d₅	Inhibitor	≥99.0%
Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.

HY-P1415A

Norleual TFA	Inhibitor	99.32%
Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.

HY-15735

c-Met inhibitor 1	Inhibitor	99.26%
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

HY-148794

Risvodetinib	Inhibitor	99.21%
Risvodetinib is a potent protein tyrosine kinase inhibitor. Risvodetinib involves in synthesis of Abelson protein kinases (c-Abl1, c-Abl2, and c-kit) inhibitor.

HY-132844

Tunlametinib	Inhibitor	98.25%
Tunlametinib, an antineoplastic agent, is a tyrosine kinase inhibitor.

Name
Email *

	Sorry, but the email address you supplied was invalid.

c-Met/HGFR

c-Met/HGFR

c-Met/HGFR Related Products (160)

Recombinant Proteins (15)

Antibodies (5)

c-Met/HGFR Related Products (160):